ScieGen Pharmaceuticals has secured FDA approval for its Abbreviated New Drug Application (ANDA) 216327, granting it market rights to the generic version of Diltiazem Hydrochloride, an oral formulation. This regulatory green light enables ScieGen to capitalize on the established generic market for this cardiovascular therapeutic.